Latest period
$9.39B
YoY change
-5.4%
5Y CAGR
-9.1%
Peak year (2019)
$39.92B
Latest annual
$5.26B
Cash on Hand history chart for AbbVie (ABBV) from 2010 to 2025
Latest: $5.26B
Cash on Hand growth chart for AbbVie (ABBV) from 2010 to 2025
Latest: -5.4%
Cash on Hand history table for AbbVie (ABBV) from 2010 to 2025
| 2025 | $5.26B | -5.4% | −$298.00M | ||
| 2024 | $5.55B | -56.7% | −$7.26B | ||
| 2023 | $12.82B | +38.9% | +$3.59B | ||
| 2022 | $9.23B | -6.1% | −$601.00M | ||
| 2021 | $9.83B | +15.9% | +$1.35B | ||
| 2020 | $8.48B | -78.8% | −$31.45B | ||
| 2019 | $39.92B | +395.3% | +$31.86B | ||
| 2018 | $8.06B | -17.7% | −$1.73B | ||
| 2017 | $9.79B | +52.4% | +$3.37B | ||
| 2016 | $6.42B | -23.6% | −$1.98B | ||
| 2015 | $8.41B | +0.4% | +$33.00M | ||
| 2014 | $8.37B | -15.4% | −$1.52B | ||
| 2013 | $9.89B | +24.1% | +$1.92B | ||
| 2012 | $7.98B | +1121.4% | +$7.32B | ||
| 2011 | $653.00M | +5960.3% | +$642.23M | ||
| 2010 | $10.78M | — | — |
- 2025$5.26B-5.4%
- 2024$5.55B-56.7%
- 2023$12.82B+38.9%
- 2022$9.23B-6.1%
- 2021$9.83B+15.9%
- 2020$8.48B-78.8%
- 2019$39.92B+395.3%
- 2018$8.06B-17.7%
- 2017$9.79B+52.4%
- 2016$6.42B-23.6%
- 2015$8.41B+0.4%
- 2014$8.37B-15.4%
- 2013$9.89B+24.1%
- 2012$7.98B+1121.4%
- 2011$653.00M+5960.3%
- 2010$10.78M—
Cash on Hand values are taken from AbbVie's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's latest reported cash and short-term investments is $9.39B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, AbbVie (ABBV) reported cash and short-term investments of $5.26B – declined 5.4% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AbbVie cash and short-term investments compounded at -9.1% per year, with a net decline across the window.
AbbVie cash and short-term investments plunged from $39.92B in 2019 to $5.26B in 2025, a 86.8% drawdown.
Across the available history, cash and short-term investments reached its high of $39.92B in 2019 and its low of $10.78M in 2010.
AbbVie Cash on Hand by Year
AbbVie Cash on Hand 2025: $5.26B
In 2025, AbbVie reported cash and short-term investments of $5.26B, declined 5.4% below 2024.
AbbVie Cash on Hand 2024: $5.55B
AbbVie cash and short-term investments in 2024 was $5.55B, plunged 56.7% below 2023.
AbbVie Cash on Hand 2023: $12.82B
2023's cash and short-term investments for AbbVie came in at $12.82B, surged 38.9% from 2022.
AbbVie Cash on Hand 2022: $9.23B
AbbVie posted cash and short-term investments of $9.23B in 2022, declined 6.1% below 2021.
AbbVie Cash on Hand 2021: $9.83B
AbbVie cash and short-term investments in 2021 was $9.83B.
See more financial history for AbbVie (ABBV).
Sector peers by Cash on Hand
Healthcare peers of AbbVie (ABBV), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $10.11B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $4.24B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation